Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Howes

Showing results (421-430 of 443) with videos related to

Pageof 45
Sort By:
Journal of Psychopharmacology (Oxford, England)|May 21, 2022
Individual and combined effects of cannabidiol and Δ<sup>9</sup>-tetrahydrocannabinol on striato-cortical connectivity in the human brainMatthew B Wall, Tom P Freeman, Chandni Hindocha, et al.
Science Translational Medicine|October 5, 2018
GABA<sub>A</sub> receptor availability is not altered in adults with autism spectrum disorder or in mouse modelsJamie Horder, Max Andersson, Maria A Mendez, et al.
Schizophrenia (Heidelberg, Germany)|July 19, 2022
Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA studyKira Griffiths, Alice Egerton, Edward Millgate, et al.
Molecular Psychiatry|June 24, 2024
Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: An umbrella reviewNathan T M Huneke, Jay Amin, David S Baldwin, et al.
Spanish Journal of Psychiatry and Mental Health|June 24, 2026
Two decades of progress in schizophrenia: evolution, current insights, and future directionsMario Alvarez-Jimenez, Celso Arango, Benedicto Crespo-Facorro, et al.
The Lancet. Psychiatry|April 3, 2025
INTEGRATE: international guidelines for the algorithmic treatment of schizophreniaRobert A McCutcheon, Toby Pillinger, Ioana Varvari, et al.
Wellcome Open Research|April 18, 2024
Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studiesSpyridon Siafis, Robert McCutcheon, Virginia Chiocchia, et al.
Brain : a Journal of Neurology|December 1, 2025
Immune alterations in schizophrenia and the effects of a therapeutic antibody: a neuroimaging studyYuya Mizuno, Ines Carreira Figueiredo, Toby Pillinger, et al.
F1000Research|January 23, 2025
Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysisSpyridon Siafis, Nobuyuki Nomura, Johannes Schneider-Thoma, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 3, 2020
The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disordersPak Wing Calvin Cheng, Wing Chung Chang, Gladys G Lo, et al.
Pageof 45

Showing results (421-430 of 443) with videos related to

Sort By:
Pageof 45
Journal of Psychopharmacology (Oxford, England)|May 21, 2022
Individual and combined effects of cannabidiol and Δ<sup>9</sup>-tetrahydrocannabinol on striato-cortical connectivity in the human brainMatthew B Wall, Tom P Freeman, Chandni Hindocha, et al.
Science Translational Medicine|October 5, 2018
GABA<sub>A</sub> receptor availability is not altered in adults with autism spectrum disorder or in mouse modelsJamie Horder, Max Andersson, Maria A Mendez, et al.
Schizophrenia (Heidelberg, Germany)|July 19, 2022
Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA studyKira Griffiths, Alice Egerton, Edward Millgate, et al.
Molecular Psychiatry|June 24, 2024
Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: An umbrella reviewNathan T M Huneke, Jay Amin, David S Baldwin, et al.
Spanish Journal of Psychiatry and Mental Health|June 24, 2026
Two decades of progress in schizophrenia: evolution, current insights, and future directionsMario Alvarez-Jimenez, Celso Arango, Benedicto Crespo-Facorro, et al.
The Lancet. Psychiatry|April 3, 2025
INTEGRATE: international guidelines for the algorithmic treatment of schizophreniaRobert A McCutcheon, Toby Pillinger, Ioana Varvari, et al.
Wellcome Open Research|April 18, 2024
Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studiesSpyridon Siafis, Robert McCutcheon, Virginia Chiocchia, et al.
Brain : a Journal of Neurology|December 1, 2025
Immune alterations in schizophrenia and the effects of a therapeutic antibody: a neuroimaging studyYuya Mizuno, Ines Carreira Figueiredo, Toby Pillinger, et al.
F1000Research|January 23, 2025
Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysisSpyridon Siafis, Nobuyuki Nomura, Johannes Schneider-Thoma, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 3, 2020
The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disordersPak Wing Calvin Cheng, Wing Chung Chang, Gladys G Lo, et al.
Pageof 45